Kyverna Therapeutics is progressing its drug mivocabtagene autoleucel for autoimmune diseases, targeting approval for stiff person syndrome. Updated trial data show all 26 patients stopped chronic immunotherapies at 16 weeks, with 81% reporting improved mobility, boosting regulatory confidence. The company is submitting a rolling Biologics License Application, aiming for completion by late 2026 and potential approval by mid-2027, with key phase 2/3 data in myasthenia gravis expected soon. Kyverna's cash runway extends into 2028, but a significant equity raise may be needed in 2027 due to a narrow margin before commercialization and a limited initial market size.
The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, at an 8.4% CAGR. This growth is driven by increased R&D investments, rising chronic diseases, and the expansion of biologics, personali...
Starlink Mobile, launched by VEON Ltd. across Ukraine, Kazakhstan, and Bangladesh, has connected over 11 million users in less than a year. The service enables existing 4G phones to access satellite connectivity where terrestrial signals are unavaila...
Medallion Financial Corp. announced it will repurchase $15 million in trust preferred securities from BIMIZCI Fund LLC at 73.66% of face value, costing about $11.05 million plus accrued distributions. This deal includes a five-year standstill agreeme...
Belite Bio, a clinical-stage drug developer focused on retinal diseases, has been approved to move its stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, the highest tier on Nasdaq. This uplisting reflects the company's ...
Heineken N.V. has repurchased a total of 8,865,521 shares under the second tranche of its €1.5 billion share buyback program, spending €629.4 million as of October 16, 2026. This includes shares bought on the exchange and from Heineken Holding N.V. T...
